Prostate News Archive
18-May-2008
Baseline PSA Reading A Reliable Prostate Cancer Predictor For Up To 30 Years (Medical News Today)
Premalignant phases of prostate cancer occur over long periods of time and a single prostate-specific antigen (PSA) reading taken at age 44-50 can help predict prostate cancer diagnosis up to 30 years subsequently, according to updated data from researchers in New York and Malmo, Sweden. The findings expand the previously established baseline age-to-diagnosis interval. Active Surveillance A Viable Option For Low-Risk Prostate Cancer (Medical News Today)
Active surveillance remains a viable option for low-risk, localized prostate cancer, according to two studies presented during the Annual Scientific Meeting of the American Urological Association (AUA), yet researchers point out a strong need for regular monitoring and development of stronger clinical predictors of progression. New Gene Methylation Test For Prostate Cancer Available (Medical News Today)
Veridex, LLC announced that its licensing collaborator, Laboratory Corporation of America Holdings (LabCorp), has commercially launched a new gene methylation test for prostate cancer. The new assay uses the biological specificity of 'DNA methylation' in prostate cancer, detecting the methylation of the gene GST-Pi. LabCorp launches new commercial test for prostate cancer (BizJournals)
Laboratory Corp. of America Holdings said Friday it will launch the first commercial gene methylation test for key tissue markers in prostate cancer.
Back to Prostate News Archive
